“Peter’s broad experience across important Pharmaceutical industries will add a valuable perspective to our Board of Directors, and will insure that Vaxeal continues in the right direction,” said Christopher Samuelson, Chairman.
“We appreciate Peter’s willingness to serve as a Director and look forward to benefitting from his advice,” added Ahmed Bouzidi, Founder and CEO.
Created in 2009, Vaxeal Holding SA is an SME headquartered in Vevey (Switzerland). The company, in partnership with leading International Research Institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families. Our initial programs have reached the pre-clinical stage in major disease segments, and are expected to enter into clinical trials in Europe in 2016. Vaxeal is member of Vaccines Europe, and the European Biopharmaceutical Enterprises. The company received a special MIT award for “its remarkable breakthrough in the field of vaccines”.
- Posted by Elliot Willcox
- On 11 December 2015
- 0 Comments